Summary & Overview
HCPCS Q5120: Injection, pegfilgrastim-bmez (Ziextenzo), 0.5 mg
HCPCS Level II code Q5120 designates injection of pegfilgrastim-bmez (Ziextenzo), a biosimilar pegfilgrastim product in a 0.5 mg presentation. This code is used when administering a therapeutic granulocyte colony-stimulating factor to reduce chemotherapy-associated febrile neutropenia risk, making it a clinically relevant item across oncology care settings nationwide. Payers commonly recognizing this code include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare and Medicare.
Readers will find a concise overview of clinical context for biosimilar pegfilgrastim use, typical sites of service such as outpatient oncology infusion centers and physician offices, and coverage landscape considerations. The publication summarizes benchmarks and reimbursement themes for Q5120, highlights policy and coding updates that affect billing for biosimilar injectables, and outlines practical billing considerations tied to service line and claim submission. Clinical relevance is emphasized because use of biosimilars like pegfilgrastim-bmez can influence access to supportive cancer care and cost dynamics at a national level.
Data not available in the input for specific payor rates, associated taxonomies, ICD-10 pairings, or related codes.
Billing Code Overview
HCPCS Level II code Q5120 describes an injection of pegfilgrastim-bmez (Ziextenzo), a biosimilar formulation, in a 0.5 mg dose. This code corresponds to administration of a granulocyte colony-stimulating factor biosimilar used to reduce the incidence of infection in patients receiving myelosuppressive chemotherapy.
Service type: Therapeutic injection (biosimilar biologic)
Typical site of service: Outpatient clinic, oncology infusion center, or physician office
Clinical & Coding Specifications
Clinical Context
A typical patient is an adult receiving myelosuppressive chemotherapy for a solid tumor (for example, breast cancer) or hematologic malignancy who requires prophylaxis against chemotherapy-induced neutropenia. The clinician orders a single subcutaneous dose of Q5120 (pegfilgrastim-bmez, Ziextenzo) 0.5 mg as part of a cycle-based regimen. The workflow: the oncology clinic documents the indication and last chemotherapy date; verifies patient identity, allergies, and prior reactions to colony-stimulating factors; obtains consent; prepares the prefilled syringe or on-body injector; administers Q5120 subcutaneously in the clinic or documents administration at home by a visiting nurse; records lot number and expiration in the chart; and monitors for immediate adverse effects (injection site reaction, bone pain). Billing uses the Q5120 HCPCS Level II code with an appropriate encounter modifier and links to the patient’s chemotherapy cycle and ICD-10 diagnosis for payer adjudication. Typical site of service is an outpatient oncology clinic, infusion center, or home health setting when administered by a qualified clinician or nurse.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
00 | No modifier (standard) |